Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

This is centered on its hotly popular drug Wegovy. Before market open, Novo Nordisk announced the launch of its NovoCare Pharmacy, a direct-to-patient delivery service for its best-selling Wegovy ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy ...

In mouse thymocytes, positive regulation of inducible T cell kinase (ITK) membrane recruitment by InsP 4 establishes a feedback loop of phospholipase Cγ1 activation downstream of the T cell ...

A key driver of this growth is the company’s de novo strategy, according to executives of its parent company, Tenet Healthcare, who discussed the strategy during a Feb. 12 earnings call. Here are five ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that had ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

In response to the Hims & Hers TV ad, Novo Nordisk — the manufacturer of Ozempic and Wegovy — put out a print ad in the New York Times and USA Today stating, “Do you really know what you ...